Clinical Trials Logo

Anaplastic Meningioma clinical trials

View clinical trials related to Anaplastic Meningioma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05793034 Recruiting - Meningioma Clinical Trials

Predictive Factors for Survival in Aggressive Meningiomas

23Men
Start date: January 7, 2021
Phase: N/A
Study type: Interventional

The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.

NCT ID: NCT04541082 Recruiting - Glioblastoma Clinical Trials

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Start date: October 26, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) neoplasms.

NCT ID: NCT03016091 Recruiting - Clinical trials for Anaplastic Meningioma

A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Start date: February 20, 2018
Phase: Phase 2
Study type: Interventional

A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

NCT ID: NCT02973256 Recruiting - Clinical trials for Anaplastic Meningioma

Oncological Care for Patients With Meningioma

ATYPICMENING
Start date: January 1, 2019
Phase:
Study type: Observational

Meningiomas with malignant components include grade II meningiomas (GIIM, the most common ones) and grade III meningiomas (GIIIM). They represent 5-35% of all meningiomas. Histological diagnosis of GIIM criteria were changed in 2007 and might be viewed by some as being quite subjective. "Standards of care" and consensus do not exist for GIIM, particularly in regards to performing, or not, radiotherapy after surgery. One other limitation in the literature is lack of data on health-related quality of life (HRQoL). Clinical trials for GIIM are very difficult to conduct. No results have been made available. Here, we propose to study clinical, pathological, radiological and therapeutic factors of an exhaustive population of GIIM and GIIIM patients, at national level. The main objective (for GIIM) is to assess the impact of postoperative radiotherapy, or the absence of postoperative radiotherapy, on overall survival and on quality of life